Replimune Group closed at $20.69 on Nov 4, up 0.19% — matching its 52-week closing high. Volume of 3.2M shares was 1.12× its 20-day average (close to normal).
Split-adjusted performance: +56.2% over one month, +501.5% over six months.
Short interest was 23.2M shares at the Oct 15 settlement (29.6% of float, 12.7 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| REPLReplimune Group | $20.69 | +0.19% | +501.5% | — | — | — | $1.96B | |
| VIRVir Biotechnology | $11.77 | +4.90% | +14.4% | +19582.5% | 33.5% | — | $1.99B | Compare |
| MAZEMaze Therapeutics | $33.38 | +3.50% | +26.1% | — | — | — | $1.85B | Compare |
| BCRXBioCryst Pharmaceuticals | $8.24 | −3.85% | −6.7% | +33.6% | 35.9% | — | $2.11B | Compare |
| COAGHemab Therapeutics Holdings | $45.09 | +4.62% | — | — | — | — | $2.11B | Compare |
| NVAXNovavax | $10.65 | +10.02% | +13.8% | −76.3% | −94.2% | — | $1.76B | Compare |
| RXRXRecursion Pharmaceuticals | $3.88 | +5.43% | +13.1% | +258.5% | −641.6% | — | $2.32B | Compare |
| VCELVericel | $45.48 | +10.68% | +23.7% | +22.5% | 2.8% | 96.2 | $2.33B | Compare |
| ADMAADMA Biologics | $10.48 | −5.67% | +4.0% | +2.0% | 30.4% | 13.9 | $2.35B | Compare |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
